Tumor heterogeneity and diverse resistance mechanisms—including alterations in ESR1 and PIK3CA—complicate treatment decisions in the post-CDK4/6i setting. ... Long-term breast cancer response to ...

A new AI tool, AAnet, has discovered five distinct cell types within tumors, offering a deeper look into cancer's inner ...

A recent study shows how extrachromosomal DNA contributes to tumor heterogeneity and may drive cancer progression. ... (CCND1 and CDK4), signal transduction (EGFR, ERBB2, ...

More information: Vishnu Kumarasamy et al, Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle, Nature Communications (2025). DOI: 10. ...

A multinational team of researchers, co-led by the Garvan Institute of Medical Research, has developed and tested a new AI ...

A new review was published in Genes & Cancer on August 25, 2022, entitled, “CDK4: a master regulator of the cell cycle and its role in cancer.” ...

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to ...

The researchers also wanted to develop a method for observing how individual tumor organoids respond to therapy in real time. Scientists commonly use endpoint assays to assess a drug’s effect on an ...

Previous research has shown that when inhibitors take out CDK4 and CDK6, CDK2 comes to the rescue. The new study shows that the reverse is also true. The power of co-drugging. In follow-up experiments ...

Impact of Tumor Heterogeneity on Testing Reliability. Although ovarian cancer shows relatively limited spatial and temporal heterogeneity compared to other cancers, ...

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to ...